Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | DHODH | Q02127 | 4/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | NUDT1 | P36639 | 3/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7635103 | 0.79 | ADORA2A (0.56) | DHODHPDE10AMEN1KMT2ANUDT1 | |
| SCHEMBL28027778 | 0.77 | ESR1 (0.50) | L3MBTL1KMT2ALMNAMAPTALDH1A1 | |
| SCHEMBL30537037 | 0.77 | NUDT1 (0.61) | L3MBTL1DHODHPDE10AMEN1KMT2A | |
| SCHEMBL729919 | 0.77 | NUDT1 (0.61) | L3MBTL1DHODHPDE10AMEN1KMT2A | |
| SCHEMBL16863668 | 0.76 | ELANE (0.44) | DHODHPDE10ANUDT1ADORA2ALMNA | |
| SCHEMBL21933862 | 0.75 | L3MBTL1 (0.42) | L3MBTL1DHODHPDE10AMEN1KMT2A | |
| Iodide SCHEMBL31032485 | 0.75 | NUDT1 (0.59) | L3MBTL1DHODHPDE10AMEN1KMT2A | |
| SCHEMBL19472017 | 0.74 | CYP1A2 (0.49) | MEN1KMT2ALMNAMAPTALDH1A1 | |
| SCHEMBL11962189 | 0.74 | NUDT1 (0.57) | L3MBTL1DHODHPDE10AMEN1KMT2A | |
| SCHEMBL21934465 | 0.73 | MEN1 (0.54) | L3MBTL1DHODHMEN1KMT2ANUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1720835-B1 | NOVEL GUANIDINYL-SUBSTITUTED HYDROXY-6-PHENYLPHENANTHRIDINES AS EFFECTIVE PHOSPHODIESTERASE (PDE) 4 INHIBITORS | NYCOMED GMBH (DE) | 2012-12-12 | — | — | EP | disclosed |
| US-8329906-B2 | Guanidinyl-substituted hydroxy-6-phenylphenanthridines | NYCOMED GMBH (DE) | 2012-12-11 | — | — | US | disclosed |
| US-8329906-B2 | Guanidinyl-substituted hydroxy-6-phenylphenanthridines | NYCOMED GMBH (DE) | 2012-12-11 | — | — | US | disclosed |
| CN-1926113-B | Novel amido substituted hydroxy-6-phenylphenanthridines and their use as PDE4 inhibitors | NYCOMED GMBH | 2010-06-23 | — | — | CN | disclosed |
| US-20100035913-A1 | Novel guanidinyl-substituted hydroxy-6-phenylphenanthridines as effective phosphodiestrase (PDE) 4 inhibitors | NYCOMED GMBH (DE) | 2010-02-11 | — | — | US | disclosed |
| US-20100035913-A1 | Novel guanidinyl-substituted hydroxy-6-phenylphenanthridines as effective phosphodiestrase (PDE) 4 inhibitors | NYCOMED GMBH (DE) | 2010-02-11 | — | — | US | disclosed |
| US-7585872-B2 | Guanidinyl-substituted hydroxy-6-phenylphenanthridines as effective phosphodiesterase (PDE) 4 inhibitors | NYCOMED GMBH (DE) | 2009-09-08 | — | — | US | disclosed |
| US-7585872-B2 | Guanidinyl-substituted hydroxy-6-phenylphenanthridines as effective phosphodiesterase (PDE) 4 inhibitors | NYCOMED GMBH (DE) | 2009-09-08 | — | — | US | disclosed |
| US-20080161339-A1 | Novel Thio-Containing Hydroxy-6-Phenylphenanthridines and their Use as Pde4 Inhibitors | ALTANA PHARMA AG (DE) | 2008-07-03 | — | — | US | disclosed |
| US-20080161339-A1 | Novel Thio-Containing Hydroxy-6-Phenylphenanthridines and their Use as Pde4 Inhibitors | ALTANA PHARMA AG (DE) | 2008-07-03 | — | — | US | disclosed |
| EP-1745025-A2 | NOVEL ISOAMIDO-SUBSTITUTED HYDROXY-6-PHENYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | Altana Pharma AG (DE) | 2007-01-24 | — | — | EP | disclosed |
| EP-1725532-A1 | NOVEL DIFLUOROETHOXY-SUBSTITUTED HYDROXY-6-PHENYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | Altana Pharma AG (DE) | 2006-11-29 | — | — | EP | disclosed |
| EP-1725534-A1 | NOVEL AMIDO-SUBSTITUTED HYDROXY-6-PHENYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | Altana Pharma AG (DE) | 2006-11-29 | — | — | EP | disclosed |
| EP-1725533-A1 | NOVEL THIO CONTAINING HYDROXY-6-PHENYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | Altana Pharma AG (DE) | 2006-11-29 | — | — | EP | disclosed |
| EP-1720835-A1 | NOVEL GUANIDINYL-SUBSTITUTED HYDROXY-6-PHENYLPHENANTHRIDINES AS EFFECTIVE PHOSPHODIESTERASE (PDE) 4 INHIBITORS | Altana Pharma AG (DE) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005087744-A1 | NOVEL THIO-CONTAINING HYDROXY-6-PHENYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | ALTANA PHARMA AG (DE) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005087745-A1 | NOVEL AMIDO-SUBSTITUTED HYDROXY-6-PHENYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | ALTANA PHARMA AG (DE) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005085203-A1 | NOVEL DIFLUOROETHOXY-SUBSTITUTED HYDROXY-6-PHENYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | ALTANA PHARMA AG (DE) | 2005-09-15 | — | — | WO | disclosed |
| WO-2005084104-A2 | NOVEL ISOAMIDO-SUBSTITUTED HYDROXY-6-PHENYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | ALTANA PHARMA AG (DE) | 2005-09-15 | — | — | WO | disclosed |
| WO-2005077906-A1 | NOVEL GUANIDINYL-SUBSTITUTED HYDROXY-6-PHENYLPHENENTHRIDINES AS EFFECTIVE PHOSPHODIESTERASE (PDE) 4 INHIBITORS | ALTANA PHARMA AG (DE) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161339-A1 | Novel Thio-Containing Hydroxy-6-Phenylphenanthridines and their Use as Pde4 Inhibitors | PDE4A, PDE4B, PDE4C | L3MBTL1 3340/4885DHODH 148/4885PDE10A 15/4885 |
| US-20100035913-A1 | Novel guanidinyl-substituted hydroxy-6-phenylphenanthridines as effective phosphodiestrase (PDE) 4 inhibitors | PDE4A, PDE4B, PDE4C | L3MBTL1 3104/4885DHODH 334/4885PDE10A 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.